Sun Pharma Q2 net profit falls 36% on one-time charges, revenue rises 12%
Exceptional charges of Rs 1,268.8 crore, including a US antitrust settlement and Organon acquisition costs, weighed on profit, while India formulation sales grew 17.3 per cent
We haven't written up this one. Business Standard IN has the full story — the link below goes straight to it.